CAM
ESPR

ClariVest Asset Management’s Esperion Therapeutics ESPR Stock Holding History

ClariVest Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-65,304
Closed -$3.35M – 782
2020
Q2 		$3.35M Buy
65,304
+2,382
+4% +$99.7K 0.09% 165
2020
Q1 		$1.98M Sell
62,922
-3,313
-5% -$175K 0.06% 199
2019
Q4 		$3.95M Sell
66,235
-21,742
-25% -$978K 0.09% 165
2019
Q3 		$3.23M Sell
87,977
-1,000
-1% -$39.6K 0.07% 202
2019
Q2 		$4.14M Buy
+88,977
New +$4.18M 0.09% 181

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ClariVest Asset Management's ESPR Position: Q3 2020 in Review

ClariVest Asset Management sold out of Esperion Therapeutics (ESPR) in Q3 2020, closing a stake of 65,304 shares — an estimated $3.35M sold.

ClariVest Asset Management first reported a position in ESPR in Q2 2019 and held it in 5 quarters. The position peaked at $4.14M in Q2 2019. 166 funds tracked by Wall St. Rank hold ESPR as of Q3 2020.

  • ClariVest Asset Management reported no remaining Esperion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • ClariVest Asset Management sold 65,304 Esperion Therapeutics shares in Q3 2020, an estimated $3.35M.
  • ClariVest Asset Management first reported a position in Esperion Therapeutics in Q2 2019 and held it in 5 quarters.
  • ClariVest Asset Management's Esperion Therapeutics position peaked at $4.14M in Q2 2019.
  • 166 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2020.

Based on ClariVest Asset Management's 13F filing for Q3 2020, filed 9 Nov 2020.